^
Association details:
| Biomarker: | HER-2 K753E |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Nerlynx (neratinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer
Excerpt:
Our experiments confirmed that cell lines with the HER2 K753E mutation overexpression were indeed resistant to lapatinib but were sensitive to the irreversible TKI neratinib.
DOI:
https://doi.org/10.1158/1078-0432.CCR-15-3036
